Curanex Pharmaceuticals Inc (CURX)
NASDAQ: CURX · Real-Time Price · USD
4.710
-0.560 (-10.63%)
At close: Aug 21, 2026
Curanex Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
6
Market Cap
7.39M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 26.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
CURX News
- 3 days ago - Curanex Pharmaceuticals Inc trading halted, news pending - TheFly
- 9 days ago - Curanex Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 3 months ago - Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission - GlobeNewsWire
- 4 months ago - Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline - GlobeNewsWire
- 4 months ago - Curanex highlights patient case study in treatment of cancer cachexia - TheFly
- 4 months ago - Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care - GlobeNewsWire
- 5 months ago - Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company's Evolution Into a Broader Therapeutics Development Company - GlobeNewsWire
- 5 months ago - Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission - GlobeNewsWire